The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients
- 1 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neural Transmission
- Vol. 127 (6), 881-891
- https://doi.org/10.1007/s00702-020-02175-1
Abstract
The TANDEM investigation was carried out in 17 Italian Movement Disorder centers on behalf of a joint initiative of neurologist members of the Italian Academy for Parkinson's disease and Movement Disorders (LIMPE-DISMOV Academy) and gastroenterologist members of the Italian Society of Digestive Endoscopy (SIED) to evaluate the efficacy and tolerability of levodopa-carbidopa intestinal gel (LCIG) in patients with advanced Parkinson's disease (PD) in routine medical care. Motor scores in "ON" and OFF" state (UPDRS-III), complications of therapy (UPDRS-IV), activities of daily living, sleep disorders and quality of life were evaluated at baseline and at two follow-up assessments (FUV1 and FUV2) within the initial 12-month LCIG treatment. In 159 patients (55% males) with a mean age of 69.1 +/- 6.6 years and a diagnosis of PD since 13.6 +/- 5.5 years, the UPDRS-III total score (in "OFF") decreased from baseline (45.8 +/- 13.2) to FUV1 (41.0 +/- 17.4; p < 0.001) and FUV2 (40.5 +/- 15.5; p < 0.001), the UPDRS-IV total score decreased from baseline (8.8 +/- 2.9) to FUV1 (5.1 +/- 3.4; p < 0.001) and FUV2 (5.5 +/- 3.2; p < 0.001). The percentage of patients exhibiting freezing, dystonia, gait/walking disturbances, falls, pain and sleep disorders was significantly reduced. Twenty-eight device complications were reported and 11 (6.9%) patients prematurely terminated the study. LCIG after 12-month treatment led to sustained improvement of time spent in "OFF", complications of therapy, PD-associated symptoms and sleep disorders. LCIG tolerability was consistent with the established safety profile of LCIG.Keywords
Funding Information
- AbbVie Italy
This publication has 38 references indexed in Scilit:
- Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approachCurrent Medical Research and Opinion, 2018
- Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson diseaseJournal of Neural Transmission, 2018
- Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's diseaseNeurodegenerative Disease Management, 2018
- Medical and Surgical Management of Advanced Parkinson's DiseaseMovement Disorders, 2018
- Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registryParkinsonism & Related Disorders, 2017
- Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomesParkinsonism & Related Disorders, 2014
- Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine careJournal of Neural Transmission, 2013
- Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?Journal of Neural Transmission, 2013
- Parkinson’s disease: The non-motor issuesParkinsonism & Related Disorders, 2011
- Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinsonʼs DiseaseCNS Drugs, 2010